A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP397994
下载链接
链接失效反馈官方服务：
资源简介：
Molecular targeted therapy has shown potential in hepatocellular carcinoma (HCC) patients, and immunotherapy applications are developing rapidly. However, clinical guidance for making individualized therapy decisions for HCC patients remains lacking. To facilitate individualized and reasonable clinical guidance for each HCC patient, we constructed the MDH score. Overall design: Sorafenib-resistant HCC cell lines generated from Huh7 and HepG2 parental cells were cultured
创建时间：
2022-10-29
